News | ECG | April 12, 2022

Biotricity to Launch Commercial Sales of Cardiac Monitoring Device Biotres

Company reports pre-order sales from existing customers of its wireless wearable device for early detection of cardiac arrhythmias.

Biotres device

Biotres device


April 12, 2022 – Biotricity, a medical diagnostic and consumer healthcare technology company, will officially launch the commercial sales of its FDA cleared, wireless wearable cardiac monitoring device, Biotres, in April 2022. The product has been available for pre-orders to physicians, medical offices, hospitals and individual use since late-February 2022.

Biotres is the company’s revolutionary technology that represents the future of Remote Patient Monitoring and the delivery of real-time diagnostic data. It serves as a three-lead device designed to continuously record electrocardiogram (ECG) data for early detection of cardiac arrhythmias, disrupting the conventional one-lead patch Holter monitor which takes longer analysis time and diagnosis time.

Biotres received FDA 510(k) clearance in January 2022, opening up a new market and expanding Biotricity’s total addressable market to $5.7 Billion. Since taking pre-orders last month, the Company has experienced strong demand for Biotres from existing customers. The Company has plans to roll out additional complementary products throughout 2022, following the same approach as Biotres. Each solution will grow the company’s TAM, creating new revenue streams for existing customers while expanding its customer base.

Dr. Waqaas Al-Siddiq, Biotricity Founder and CEO, commented, “After months of anticipation, our Biotres product is finally available for sale. Judging by the amount of pre-order interest we’ve seen since February, Biotres can provide millions of individuals with an early detection method to easily and efficiently record cardiac arrhythmias. We are optimally positioned to penetrate a $2 billion-dollar holter market that needs a faster and more efficient approach, critical to improving patient lives.”

For more information: https://www.biotricity.com/biotres/


Related Content

Feature | Holter Monitoring Systems | By Jiang Li, PhD

Holter monitors are firmly ensconced as the standard device for remote cardiac monitoring. But does that make them the ...

Home August 23, 2022
Home
News | Holter Monitoring Systems

September 27, 2016 — BioTelemetry Inc. announced in late August that the company has received CE mark approval of its ...

Home September 27, 2016
Home
Feature | Holter Monitoring Systems | Judy Lenane, RN, MHA

One-third of ischemic strokes are classified as cryptogenic. The classic risk factors for stroke are usually absent ...

Home November 16, 2015
Home
Subscribe Now